Search Results - "Hiraku, Fukushima"

A Prospective Observational Study on Effect of Short‐Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO‐01) by Nakamura, Michio, Ishiguro, Atsushi, Muranaka, Tetsuhito, Fukushima, Hiraku, Yuki, Satoshi, Ono, Kota, Murai, Taichi, Matsuda, Chika, Oba, Ayane, Itaya, Kazufumi, Sone, Takayuki, Yagisawa, Masataka, Koike, Yuta, Endo, Ayana, Tsukuda, Yoko, Ono, Yuji, Kudo, Takahiko, Nagasaka, Atsushi, Nishikawa, Shuji, Komatsu, Yoshito

“…Background A multicenter prospective observational study evaluated the effect of gastrointestinal cancer chemotherapy with short‐term periodic steroid…”
Get full text

Open‐label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron by Komatsu, Yoshito, Okita, Kenji, Yuki, Satoshi, Furuhata, Tomohisa, Fukushima, Hiraku, Masuko, Hiroyuki, Kawamoto, Yasuyuki, Isobe, Hiroshi, Miyagishima, Takuto, Sasaki, Kazuaki, Nakamura, Michio, Ohsaki, Yoshinobu, Nakajima, Junta, Tateyama, Miki, Eto, Kazunori, Minami, Shinya, Yokoyama, Ryoji, Iwanaga, Ichiro, Shibuya, Hitoshi, Kudo, Mineo, Oba, Koji, Takahashi, Yasuo

“…The purpose of this study is to compare the efficacy of a single administration of dexamethasone (DEX) on day 1 against DEX administration on days 1–3 in…”
Get full text

Three cases of acute or fulminant hepatitis E caused by ingestion of pork meat and entrails in Hokkaido, Japan: Zoonotic food-borne transmission of hepatitis E virus and public health concerns by Miyashita, Kencho, Kang, Jong-Hon, Saga, Akiyoshi, Takahashi, Kazuaki, Shimamura, Tsuyoshi, Yasumoto, Atsushi, Fukushima, Hiraku, Sogabe, Susumu, Konishi, Kouhei, Uchida, Takumi, Fujinaga, Akira, Matsui, Takeshi, Sakurai, Yasuo, Tsuji, Kunihiko, Maguchi, Hiroyuki, Taniguchi, Masahiko, Abe, Natsumi, Fazle Akbar, Sheikh Mohammad, Arai, Masahiro, Mishiro, Shunji

“…Aim:  In developed countries including Japan, the transmission route of indigenous hepatitis E virus (HEV) infection is obscure. Accordingly, public health…”
Get full text

Supertopcolor by Fukushima, Hiraku, Kitano, Ryuichiro, Yamaguchi, Masahiro

“…We consider a supersymmetric QCD with soft supersymmetry breaking terms as the dynamics for the electroweak symmetry breaking. We find various advantages…”
Get full text

Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer by Kawamoto, Yasuyuki, Komatsu, Yoshito, Yuki, Satoshi, Sawada, Kentaro, Muranaka, Tetsuhito, Harada, Kazuaki, Nakatsumi, Hiroshi, Fukushima, Hiraku, Ishiguro, Atsushi, Dazai, Masayoshi, Hatanaka, Kazuteru, Nakamura, Michio, Iwanaga, Ichiro, Uebayashi, Minoru, Sogabe, Susumu, Kobayashi, Yoshimitsu, Miyagishima, Takuto, Ono, Kota, Sakamoto, Naoya, Sakata, Yuh

“…In Japan, S-1 plus cisplatin (SP) regimen has become a standard therapy for patients with advanced gastric cancer. Moreover, the S-1 plus oxaliplatin regimen…”
Get full text

Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing by Bando, Hideaki, Tsuchihara, Katsuya, Yoshino, Takayuki, Kojima, Motohiro, Ogasawara, Naomi, Fukushima, Hiraku, Ochiai, Atsushi, Ohtsu, Atsushi, Esumi, Hiroyasu

“…The concordance of KRAS mutation detection between the amplification refractory mutation system-Scorpion assay and direct sequencing was evaluated with…”
Get full text

Gravitino thermal production revisited and a new cosmological scenario of gauge mediation by Fukushima, Hiraku, Kitano, Ryuichiro

“…A bstract We present a new scenario of gravitino dark matter which is compatible with the thermal leptogenesis. We confirm by an explicit calculation in…”
Get full text

Cosmologically viable gauge mediation by Fukushima, Hiraku, Kitano, Ryuichiro, Takahashi, Fuminobu

“…A bstract Gauge mediation provides us with a complete picture of supersymmetry breaking and its mediation within the effective field theories, and thus allows…”
Get full text

Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP by Kobayashi, Yoshimitsu, Komatsu, Yoshito, Yuki, Satoshi, Fukushima, Hiraku, Sasaki, Takahide, Iwanaga, Ichiro, Uebayashi, Minoru, Okuda, Hiroyuki, Kusumi, Takaya, Miyagishima, Takuto, Sogabe, Susumu, Tateyama, Miki, Hatanaka, Kazuteru, Tsuji, Yasushi, Nakamura, Michio, Konno, Jun, Yamamoto, Fumiyasu, Onodera, Manabu, Iwai, Kazuhiro, Sakata, Yuh, Abe, Riichiro, Oba, Koji, Sakamoto, Naoya

“…We planned a randomized, open-label trial to evaluate differences between pre-emptive and reactive skin treatment for panitumumab (Pmab)-associated skin…”
Get full text

Evaluation of usefulness of Royal Marsden Hospital prognostic index in second-line chemotherapy of advanced gastric cancer by Sasaki, Takahide, Komatsu, Yoshito, Yuki, Satoshi, Harada, Kazuaki, Kobayashi, Yoshimitsu, Fukushima, Hiraku, Sakamoto, Naoya

“…Abstract only 163 Background: Royal Marsden Hospital prognostic Index (RMH-I), which was based on performance status, ALP, liver metastasis and peritoneal…”
Get full text

An open, multicenter, phase II clinical trial to evaluate efficacy and safety of S-1 split cisplatin in patients with advanced gastric cancer (AGC): HGCSG0702—Safety analysis by Iwanaga, Ichiro, Yuki, Satoshi, Fukushima, Hiraku, Ishiguro, Atsushi, Takahata, Takenori, Miyagishima, Takuto, Kudo, Mineo, Uehata, Yasuko, Sakata, Yuh, Komatsu, Yoshito

“…Abstract only 121 Background: From the results of SPIRITS trial, S-1 plus cisplatin has been regarded as standard first-line chemotherapy for patients with AGC…”
Get full text

Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Final analysis—Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial by Yuki, Satoshi, Komatsu, Yoshito, Fukushima, Hiraku, Sasaki, Takahide, Amano, Toraji, Miyagishima, Takuto, Hatanaka, Kazuteru, Nakamura, Michio, Tateyama, Miki, Sakata, Yuh

“…Abstract only 460 Background: The FIRIS study (Muro K et al. Lancet Oncol 2010;11:853–860) previously demonstrated the non-inferiority of Irinotecan plus S-1…”
Get full text

Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by KRAS Exon2 status by Takahata, Takenori, Yuki, Satoshi, Nakatsumi, Hiroshi, Harada, Kazuaki, Fukushima, Hiraku, Sato, Atsushi, Kato, Takashi, Meguro, Takashi, Nakamura, Michio, Ehira, Nobuyuki, Iwanaga, Ichiro, Tateyama, Miki, Hatanaka, Kazuteru, Eto, Kazunori, Okuda, Hiroyuki, Kobayashi, Yoshimitsu, Muto, Osamu, Abe, Masakazu, Sakata, Yuh, Komatsu, Yoshito

“…Abstract only 782 Background: A few reports have shown the efficacy of bevacizumab (BV) independent of the KRAS Exon2 mutational status (KRAS). We performed a…”
Get full text

Association of morphologic response with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802 by Yuki, Satoshi, Nakatsumi, Hiroshi, Hayashi, Hideyuki, Fukushima, Hiraku, Kato, Takashi, Meguro, Takashi, Nakamura, Michio, Iwanaga, Ichiro, Eto, Kazunori, Sato, Atsushi, Okuda, Hiroyuki, Oba, Ayane, Miyagishima, Takuto, Muto, Osamu, Yabusaki, Satoshi, Miyamoto, Noriyuki, Kudo, Kohsuke, Sakamoto, Naoya, Sakata, Yuh, Komatsu, Yoshito

“…Abstract only 743 Background: It was reported that an optimal morphologic response to preoperative chemotherapy was associated with better overall survival…”
Get full text

Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in phase II study (NORTH/HGCSG1003): Detailed analysis of peripheral sensory neuropathy by Sogabe, Susumu, Yuki, Satoshi, Fukushima, Hiraku, Takahashi, Norihiko, Shichinohe, Toshiaki, Kusumi, Takaya, Nakamura, Fumitaka, Iwanaga, Ichiro, Hatanaka, Kazuteru, Miyashita, Kencho, Konno, Jun, Uemura, Kazuhito, Nenohi, Masaaki, Kina, Masaya, Sakamoto, Naoya, Taketomi, Akinobu, Hirano, Satoshi, Amano, Toraji, Ito, Yoichi M, Komatsu, Yoshito

“…Abstract only 701 Background: Oxaliplatin-containing regimen is a standard adjuvant chemotherapy for resected stage III colon cancer. Oxaliplatin-containing…”
Get full text

Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV by Hatanaka, Kazuteru, Yuki, Satoshi, Nakatsumi, Hiroshi, Fukushima, Hiraku, Naruse, Hirohito, Kato, Takashi, Meguro, Takashi, Nakamura, Michio, Iwanaga, Ichiro, Uebayashi, Minoru, Tateyama, Miki, Eto, Kazunori, Kudo, Mineo, Kato, Sosuke, Okuda, Hiroyuki, Sogabe, Susumu, Miyashita, Kencho, Sakata, Yuh, Komatsu, Yoshito

“…Abstract only 527 Background: A few reports have shown no difference between the efficacy of infusional FU and that of oral FU (Capecitabine/S-1) for…”
Get full text

Association of early tumor shrinkage with progression-free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802 by Nakatsumi, Hiroshi, Yuki, Satoshi, Muranaka, Tetsuhito, Fukushima, Hiraku, Kato, Takashi, Meguro, Takashi, Nakamura, Michio, Iwanaga, Ichiro, Ehira, Nobuyuki, Sonoda, Norikazu, Kudo, Mineo, Kato, Kanji, Miyashita, Kencho, Abe, Masakazu, Miyamoto, Noriyuki, Sakamoto, Keita, Kudo, Kohsuke, Sakamoto, Naoya, Sakata, Yuh, Komatsu, Yoshito

“…Abstract only 749 Background: It was reported that early tumor shrinkage (ETS) was associated with better overall survival (OS) in patients (pts) with…”
Get full text

Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer by Komatsu, Yoshito, Yuki, Satoshi, Sogabe, Susumu, Fukushima, Hiraku, Nakatsumi, Hiroshi, Kobayashi, Yoshimitsu, Iwanaga, Ichiro, Nakamura, Michio, Hatanaka, Kazuteru, Miyagishima, Takuto, Kudo, Mineo, Munakata, Masaki, Meguro, Takashi, Tateyama, Miki, Sakata, Yuh

“…In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and…”
Get more information

Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy by Shitara, Kohei, Yuki, Satoshi, Yamazaki, Kentaro, Naito, Yoichi, Fukushima, Hiraku, Komatsu, Yoshito, Yasui, Hirofumi, Takano, Toshimi, Muro, Kei

“…Purpose Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line…”
Get full text

Randomized phase III clinical study comparing postoperative UFT/LV,UFT+LV/UFT and UFT+LV+PSK/UFT+PSK as adjuvant therapy for curatively resected stage III colorectal cancer HGCSG-CAD study by Shichinohe, Toshiaki, Komatsu, Yoshito, Akazawa, Kohei, Yuki, Satoshi, Fukushima, Hiraku, Ohno, Kouichi, Nakamura, Fumitaka, Kusumi, Takaya, Morita, Takayuki, Senmaru, Naoto, Kumagai, Naoko, Hirano, Satoshi

“…Abstract only 3638 Background: Study showed that the oral anticancer agent UFT/LV is useful as postoperative adjuvant chemotherapy for stage III colorectal…”
Get full text